5 Appraisal Committee members and NICE project team

Appraisal Committee members

The Appraisal Committee is one of NICE's standing advisory committees. Its members are appointed for a 3-year term. A list of the Committee members who took part in the discussions for this appraisal appears below. The Appraisal Committee meets three times a month except in December, when there are no meetings. The Committee membership is split into three branches, each with a chair and vice chair. Each branch considers its own list of technologies, and ongoing topics are not moved between the branches.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Professor David Barnett (Chair)
Professor of Clinical Pharmacology, University of Leicester

Professor Philip Home (Vice Chair)
Professor of Diabetes Medicine, Newcastle University

Professor A E Ades
MRC Senior Scientist, MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol

Mrs Elizabeth Brain
Lay Member

Dr Robin Carlisle
Deputy Director of Public Health, Rotherham PCT

Mrs Fiona Duncan
Clinical Nurse Specialist, Anaesthetic Department, Blackpool Victoria Hospital, Blackpool

Dr Paul Ewings
Statistician, Taunton & Somerset NHS Trust, Taunton

Mr John Goulston
Chief Executive, Barking, Havering and Redbridge Hospitals NHS Trust

Mr Adrian Griffin
VP Strategic Affairs, LifeScan, Johnson & Johnson

Dr Richard Harling
Director of Health Policy, Worcestershire PCT and Worcestershire County Council

Dr Vincent Kirkbride
Consultant Neonatologist, Regional Neonatal Intensive Care Unit, Sheffield

Dr Alec Miners
Lecturer in Health Economics, London School of Hygiene and Tropical Medicine

Dr Ann Richardson
Lay Member

Mrs Angela Schofield
Chairman, Bournemouth and Poole Teaching PCT

Mr David Thomson
Lay Member

Dr William Turner
Consultant Urologist, Addenbrooke's Hospital

Dr Luke Twelves
General Practitioner, Ramsey Health Centre, Cambridgeshire

Mr Mike Spencer
General Manager, Cardiff and Vale NHS Trust – Facilities and Clinical Support Services

Dr Jane Adam
Department of Diagnostic Radiology, St George's Hospital

Dr David Newsham
Lecturer (Orthoptics), University of Liverpool

Professor Iain Squire
Consultant Physician, University Hospitals of Leicester

Dr James Moon
Consultant Cardiologist and Senior Lecturer, University College London Hospital (UCLH) and UCL

Dr Peter Heywood
Consultant Neurologist, Frenchay Hospital

Dr Ian Lewin
Consultant Endocrinologist, North Devon District Hospital

Mr Christopher Earl
Nurse Advisor, Medicines and Healthcare Products Regulatory Agency

NICE project team

Each technology appraisal is assigned to a team consisting of one or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Dr Andres Roman
Technical Lead

Prashanth Kandaswamy
Technical Adviser

Bijal Chandarana
Project Manager

Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group, The University of Liverpool:

  • Fleeman N, Bagust A, McLeod C, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), February 2009

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Lilly UK (pemetrexed)

Professional or specialist and patient or carer groups:

  • British Thoracic Oncology Group

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)

  • General Practice Airways Group

  • Macmillan Cancer Support

  • Marie Curie Cancer Care

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Intercollegiate Lung Cancer Group

  • Royal College of Radiologists

Other consultees:

  • Department of Health

  • Southampton City PCT

  • Welsh Assembly Government

  • West Sussex PCT

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Liverpool Reviews and Implementation Group, The University of Liverpool

  • National Collaborating Centre for Cancer

  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

  • NHS Quality Improvement Scotland

  • Sanofi Aventis

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on pemetrexed for NSCLC by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Ms Catherine Docherty, Lung Cancer Clinical Nurse Specialist, nominated by Royal College of Nursing – clinical specialist

  • Professor David Ferry, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical specialist

  • Dr Jesme Fox, nominated by Roy Castle Lung Cancer Foundation – patient expert